Trader consensus on Polymarket assigns an 81% implied probability to no Encore Medical IPO before June 2026, reflecting prolonged SEC review delays following the firm's initial S-1 filing in September 2025 and subsequent amendments through early 2026, with multiple anticipated listing dates in April and May passing without pricing or execution. The Minnesota-based medtech developer's transcatheter septal occlusion device holds EU CE Mark approval across 21 countries but awaits U.S. FDA pivotal trial completion targeted for late 2027, underscoring pre-commercialization risks amid trailing twelve-month revenue of $2.1 million and net losses of $1.6 million. Competitive pressures from incumbents like Abbott and Boston Scientific, coupled with microcap valuation at ~$49 million fully diluted, limit near-term momentum, pricing modest 8% odds into 50M–55M market cap while upcoming regulatory milestones could shift sentiment.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhậtEncore Medical IPO Closing Market Cap
Encore Medical IPO Closing Market Cap
No IPO before June 2026 81%
55M+ 7.8%
45M–50M 7%
<45M 2.8%
$24,003 KL.
$24,003 KL.
Apr 22, 2026
<45M
3%
45M–50M
7%
50M–55M
8%
55M+
8%
No IPO before June 2026
81%
No IPO before June 2026 81%
55M+ 7.8%
45M–50M 7%
<45M 2.8%
$24,003 KL.
$24,003 KL.
Apr 22, 2026
<45M
$7,323 KL.
3%
45M–50M
$2,625 KL.
7%
50M–55M
$1,759 KL.
8%
55M+
$3,121 KL.
8%
No IPO before June 2026
$9,175 KL.
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket assigns an 81% implied probability to no Encore Medical IPO before June 2026, reflecting prolonged SEC review delays following the firm's initial S-1 filing in September 2025 and subsequent amendments through early 2026, with multiple anticipated listing dates in April and May passing without pricing or execution. The Minnesota-based medtech developer's transcatheter septal occlusion device holds EU CE Mark approval across 21 countries but awaits U.S. FDA pivotal trial completion targeted for late 2027, underscoring pre-commercialization risks amid trailing twelve-month revenue of $2.1 million and net losses of $1.6 million. Competitive pressures from incumbents like Abbott and Boston Scientific, coupled with microcap valuation at ~$49 million fully diluted, limit near-term momentum, pricing modest 8% odds into 50M–55M market cap while upcoming regulatory milestones could shift sentiment.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Thị trường mở: Apr 3, 2026, 7:59 PM ET
Khối lượng
$24,003Ngày kết thúc
Apr 22, 2026Thị trường mở
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket assigns an 81% implied probability to no Encore Medical IPO before June 2026, reflecting prolonged SEC review delays following the firm's initial S-1 filing in September 2025 and subsequent amendments through early 2026, with multiple anticipated listing dates in April and May passing without pricing or execution. The Minnesota-based medtech developer's transcatheter septal occlusion device holds EU CE Mark approval across 21 countries but awaits U.S. FDA pivotal trial completion targeted for late 2027, underscoring pre-commercialization risks amid trailing twelve-month revenue of $2.1 million and net losses of $1.6 million. Competitive pressures from incumbents like Abbott and Boston Scientific, coupled with microcap valuation at ~$49 million fully diluted, limit near-term momentum, pricing modest 8% odds into 50M–55M market cap while upcoming regulatory milestones could shift sentiment.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Khối lượng
$24,003Ngày kết thúc
Apr 22, 2026Thị trường mở
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader consensus on Polymarket assigns an 81% implied probability to no Encore Medical IPO before June 2026, reflecting prolonged SEC review delays following the firm's initial S-1 filing in September 2025 and subsequent amendments through early 2026, with multiple anticipated listing dates in April and May passing without pricing or execution. The Minnesota-based medtech developer's transcatheter septal occlusion device holds EU CE Mark approval across 21 countries but awaits U.S. FDA pivotal trial completion targeted for late 2027, underscoring pre-commercialization risks amid trailing twelve-month revenue of $2.1 million and net losses of $1.6 million. Competitive pressures from incumbents like Abbott and Boston Scientific, coupled with microcap valuation at ~$49 million fully diluted, limit near-term momentum, pricing modest 8% odds into 50M–55M market cap while upcoming regulatory milestones could shift sentiment.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp